AnaptysBio

US · ANAB #3010 by market cap Listed 2017

45.65 -2.24 -4.68%

Live - 5344 symbols - heartbeat 312s ago · 2026-10-08 07:08

Pre-market 45.49 -0.35%

After-hours 45.65 0.00%

Market cap: 1.36B
P/E (TTM): 8.15
P/B: 128.95
EPS: 5.60
Div yield: 0.00%
52W pos: 49%

Reader sentiment Are you bullish or bearish on ANAB?

Anonymous reader poll. Unscientific, not investment advice.

About AnaptysBio

AnaptysBio, Inc. is a clinical-stage biotechnology company, which engages in the development of antibody product candidates. The firm’s product pipeline includes ANB030, ANB030, and Imsidolimab. It also offers the SHM platform that replicates the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Founded: 2005
CEO: Mr. Daniel R. Faga
Employees: 104
Headquarters: San Diego, California, United States of America
Fiscal year end: 12-31
Website: anaptysbio.com

Company profile

Exchange: US
Symbol: ANAB
Market-cap rank: #3010
Listing date: 2017-01-26
Market cap: 1.36B
Float cap: 933.08M
Shares out: 29.90M
Float shares: 20.44M

Sectors & themes

Biotechnology

Browse all sectors & themes

Quote time 2026-10-08 07:08:41 · For reference only, not investment advice and not tailored to your situation.